| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Repinotan HCl primarily targets the 5-HT1A receptor, a subtype of serotonin receptor. It has a very high affinity for this receptor, with Ki values of 0.19 nM in calf hippocampus, 0.25 nM in rat and human cortex, and 0.59 nM in rat hippocampus. By acting as an agonist, it mimics the effects of serotonin at this receptor.
|
|---|---|
| ln Vitro |
In vitro, Repinotan HCl's activity is characterized by its potent and selective binding to the 5-HT1A receptor. Its high affinity and selectivity make it a valuable tool for studying the role of this receptor in the central nervous system.
|
| ln Vivo |
In vivo, Repinotan HCl has been investigated for its neuroprotective and neurorestorative properties. It has been primarily studied for the treatment of ischemic stroke and other central nervous system disorders. Its ability to penetrate the BBB is crucial for its central effects.
|
| Enzyme Assay |
The binding affinity of Repinotan HCl to the 5-HT1A receptor is determined using radioligand binding assays. In these cell-free experiments, membrane preparations from tissues expressing the receptor are incubated with a radiolabeled ligand in the presence of varying concentrations of the compound. The displacement of the ligand is measured to calculate the Ki.
|
| Cell Assay |
For cellular assays, cell lines expressing the human 5-HT1A receptor are used. The compound's ability to activate the receptor is measured by assessing its effect on downstream signaling pathways, such as the inhibition of adenylyl cyclase.
|
| Animal Protocol |
In vivo, Repinotan HCl is typically administered orally or intravenously. Its efficacy is evaluated in animal models of stroke or other neurological conditions, where its neuroprotective effects are assessed by measuring infarct size or functional recovery.
|
| ADME/Pharmacokinetics |
Repinotan HCl is an orally active compound. It is soluble in DMSO at ≥10 mg/mL. Its ability to penetrate the BBB is a key pharmacokinetic property.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Repinotan HCl is not detailed in the search results. As a 5-HT1A agonist, its side effect profile would be related to serotonin receptor activation.
|
| Additional Infomation |
See also: Repinotan (Note moved to).
Repinotan HCl is a research compound that has been studied for its potential in treating neurological conditions such as ischemic stroke. Its development highlights the therapeutic potential of 5-HT1A receptor agonists in neuroprotection. It is not an approved drug. |
| Molecular Formula |
C21H24N2O4S.CLH
|
|---|---|
| Molecular Weight |
436.9522
|
| Exact Mass |
436.122
|
| CAS # |
144980-77-8
|
| Related CAS # |
Repinotan;144980-29-0
|
| PubChem CID |
198756
|
| Appearance |
Light yellow to brown solid powder
|
| Boiling Point |
599.5ºC at 760mmHg
|
| Flash Point |
316.4ºC
|
| Vapour Pressure |
2.49E-14mmHg at 25°C
|
| LogP |
4.806
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
647
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C2C(=C1)CC[C@H](CNCCCCN3C(=O)C4=CC=CC=C4S3(=O)=O)O2.Cl
|
| InChi Key |
IGKYREHZJIHPML-UNTBIKODSA-N
|
| InChi Code |
InChI=1S/C21H24N2O4S.ClH/c24-21-18-8-2-4-10-20(18)28(25,26)23(21)14-6-5-13-22-15-17-12-11-16-7-1-3-9-19(16)27-17;/h1-4,7-10,17,22H,5-6,11-15H2;1H/t17-;/m1./s1
|
| Chemical Name |
2-[4-[[(2R)-3,4-dihydro-2H-chromen-2-yl]methylamino]butyl]-1,1-dioxo-1,2-benzothiazol-3-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2886 mL | 11.4430 mL | 22.8859 mL | |
| 5 mM | 0.4577 mL | 2.2886 mL | 4.5772 mL | |
| 10 mM | 0.2289 mL | 1.1443 mL | 2.2886 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
